AURO-CEFIXIME 100 MG / 5 ML
CEFIXIME : 100 MG / 5 ML · DIN 02468689 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-CEFIXIME?
AURO-CEFIXIME 100 MG / 5 ML contains CEFIXIME : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02468689, held by AURO PHARMA INC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jan-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-CEFIXIME used for?
AURO-CEFIXIME (cefixime) is indicated in the treatment of various infections caused by susceptible strains of designated microorganisms, including upper respiratory tract infections (pharyngitis and tonsillitis), middle ear infections (otitis media), paranasal sinus infections (sinusitis), lower respiratory tract infections (acute bronchitis), and urinary tract infections (acute uncomplicated cystitis and urethritis). It is also indicated for uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02468689 |
|---|---|
| Brand name | AURO-CEFIXIME |
| Generic / active ingredient | CEFIXIME : 100 MG / 5 ML |
| Manufacturer | AURO PHARMA INC |
| Strength | 100 MG / 5 ML |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DD08 CEFIXIME |
| AHFS class | 08:12.06.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Jan-2018 |
| Original market date | 2018-01-08 00:00:00 |
How is it administered?
Pediatrics (>= 6 months): 8 mg/kg/day once daily. Adults/Children >45kg: 400 mg daily. Use once daily for UTI. Suspension must be used for otitis media. Duration typically 10-14 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
After mixing, the suspension may be kept for 14 days at room temperature (15 - 25°C) or under refrigeration. Keep container tightly closed. Shake well for at least 30 seconds before using. Discard unused portion after 14 days.
How is it supplied?
50 mL, 100 mL
Contraindications
Known allergies to cephalosporins, penicillins, or any ingredients in the formulation.
Warnings and precautions
Hypersensitivity (cross-reactivity with penicillin), Clostridium difficile-associated disease (CDAD), Hemolytic Anemia, Severe Cutaneous Adverse Reactions (SCAR), and potential for seizures.
What can be used instead?
Other Canadian products sharing ATC code J01DD08 CEFIXIME. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CEFIXIME | 400 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02432773 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SUSPENSION | ODAN LABORATORIES LTD | MARKETED | DIN 00868965 |
| SUPRAX | 400 MG | TABLET | ODAN LABORATORIES LTD | MARKETED | DIN 00868981 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SOLUTION | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02195992 |
| SUPRAX | 200 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 00868973 |
| SUPRAX | 400 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02195984 |
| SUPRAX - TAB 200MG | 200 MG | TABLET | RHONE-POULENC RORER CANADA INC. | CANCELLED POST MARKET | DIN 02195976 |
Who else supplies CEFIXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFIXIME appears in 4714 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.